Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis

Hepatology

Volumn 45, Issue 1, 2007, Pages 118-127

  Nakamura, Minoru ^a   Kondo, Hisayoshi ^a   Mori, Tsuyoshi ^a   Komori, Atsumasa ^a   Matsuyama, Mutsumi ^a   Ito, Masahiro ^a   Takii, Yasushi ^a   Koyabu, Makiko ^a   Yokoyama, Terufumi ^a   Migita, Kiyoshi ^a   Daikoku, Manabu ^a   Abiru, Seigo ^a   Yatsuhashi, Hiroshi ^a   Takezaki, Eiichi ^b   Masaki, Naohiko ^b   Sugi, Kazuhiro ^b   Honda, Koichi ^b   Adachi, Hiroshi ^b   Nishi, Hidehiro ^b   Watanabe, Yukio ^b   Nakamura, Yoko ^b   Shimada, Masaaki ^b   Komatsu, Tatsuji ^b   Saito, Akira ^b   Saoshiro, Takeo ^b   Harada, Hideharu ^b   Sodeyama, Takeshi ^b   Hayashi, Shigeki ^b   Masumoto, Akihide ^b   Sando, Takehiro ^b   Yamamoto, Tetsuo ^b   Sakai, Hironori ^b   Kobayashi, Masakazu ^b   Muro, Toyokichi ^b   Koga, Michiaki ^b   Shums, Zakera ^c   Norman, Gary L ^c   Ishibashi, Hiromi ^a   more..

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b National Hospital Organization   (Japan)

^c INOVA DIAGNOSTICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; BEZAFIBRATE; BILIRUBIN; CENTROMERE ANTIBODY; GP210 ANTIBODY; PREDNISOLONE; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; ESOPHAGUS VARICES; FEMALE; HEALTH CARE ORGANIZATION; HEPATITIS; HUMAN; HUMAN TISSUE; JAPAN; JAUNDICE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PORTAL HYPERTENSION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; ANTIGENS, NUCLEAR; AUTOANTIGENS; CENTROMERE; CHROMATIN; DISEASE PROGRESSION; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS, BILIARY; LIVER FAILURE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEAR PORE COMPLEX PROTEINS; NUCLEAR PROTEINS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33846449067     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21472     Document Type: Article

References (46)

1. Rubin E, Schaffner F, Popper H. Primary biliary cirrhosis. Am J Pathol 1965;46:387-407.
2. Prince M, Chetwynd A, Newman W, Metcalf JV, James OFW. Survival and symptoms progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up to 28 years. Gastroenterology 2002;123:1044-1051.
3. Leung PSC, Coppel RL, Ansari A, Munoz S, Gershwin ME. Antimitochondrial antibodies in primary biliary cirrhosis. Semin Liver Dis 1997; 17:61-69.
4. Courvalin JC, Worman HJ. Nuclear envelope protein autoantibodies in primary biliary cirrhosis. Semin Liver Dis 1997;17:79-90.
5. Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis 2005;25:298-310.
6. Rigopoulou EI, Davies ET, Pares A, Zachou K, Liaskos C, Bogdanos D-P, et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 2005;54:528-532.
7. Itoh S, Ichida T, Yoshida T, Hayakawa A, Uchida M, Tashiro-Itoh T, et al. Autoantibodies against a 210kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. J Gastroenterol Hepatol 1998;13:257-265.
8. Invernizzi P, Podda M, Battezzati PM, Crosignani A, Zuin M, Hitchman E, et al. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol 2001;34:366-372.
9. Muratori P, Muratori L, Ferrari R, Cassani F, Bianchi G, Lenzi M, et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003;98:431-437.
10. Miyachi K, Hankins RW, Matsushima H, Kikuchi F, Inomata T, Horigome T, et al. Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study. J Autoimmun 2003;20:247-254.
11. Zuchner D, Sternsdorf T, Szostecki C, Heathcote EJ, Cauch-Dudek K, Will H. Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. HEPATOLOGY 1997;26:1123-1130.
12. Nakamura M, Shimizu-Yoshida Y, Takii Y, Komori A, Yokoyama T, Ueki T, et al. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J Hepatol 2005;42:386-392.
13. Yang W-H, Yu JH, Nakajima A, Neuberg D, Lindor K, Bloch DB. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure. Clin Gastroenterol Hepatol 2004;2:1116-1122.
14. Wesierska-GadekJ, Penner E, Battezzati PM, Selmi C, Zuin M, Hitchman E, et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. HEPATOLOGY 2006;43:1135-1144.
15. Parveen S, Morshed SA, Nishioka M. High prevalence of antibodies to recombinant CENP-B in primary biliary cirrhosis: nuclear immunofluorescence patterns and ELISA reactivities. J Gastroenterol Hepatol 1995; 10:438-445.
16. Rigamonti C, Shand LM, Feudjo M, Bunn CC, Black CM, Denton CP, et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 2006;55:388-394.
17. Scofield RH. Autoantibodies as predictors of disease. Lancet 2004;363: 1544-1546.
18. Pihoker C, Gilliam LK, Hampe CS, Lernmark A. Autoantibodies in diabetes. Diabetes 2005;54:S52-S61.
19. van Gaalen FA, Linn-Rasker SP, van Venrooji WJ, de Jong BA, Breedveld FC, Verweij CL, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004;50:709-715.
20. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-1533.
21. Amre DK, Lu SE, Costea F, Seidman EG. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am J Gastroenterol 2006;101:645-652.
22. Degott C, Zafrani ES, Callard P, Balkau B, Poupon RE, Poupon R. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. HEPATOLOGY 1999;29: 1007-1012
23. Scheuer PJ. Primary biliary cirrhosis. Proc R Soc Med 1967;60:1257-1260.
24. Nakamura M, Takii Y, Ito M, Komori A, Yokoyama T, Shimizu-Yoshoida Y, et al. Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis. J Autoimmun 2006;26:138-145.
25. Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C. Diversity of antinuclear antibodies in progressive systemic sclerosis: anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 1980; 23:617-625.
26. Miyawaki S, Asanuma H, Nishiyama S, Yoshinaga Y. Clinical and serological heterogeneity in patients with anticentromere antibodies. J Rheumatol 2005;32:1488-1494.
27. Hossny E, Abdul HH, Mabrouk R. Anti-centromere antibodies as a marker of Raynaud's phenomenon in pediatric rheumatologic diseases. Pediatr Allergy Immunol 2000;11:250-255.
28. Makinen D, Fritzler M, Davis P, Sherlock S. Anti-centromere antibodies in primary biliary cirrhosis. Arthritis Rheum 1983;26:914-917.
29. Marasini B, Gagetta M, Rossi V, Ferrani P. Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients. Ann Rheuma Dis 2001;60:1046-1049.
30. Burlingame RW, Cervera R. Anti-chromatin (anti-nucleosome) autoantibodies. Autoimmun Rev 2002;1:321-328.
31. Portmann B, Popper H, Neuberger J, Williams R. Sequential and diagnostic features in primary biliary cirrhosis based on serial histologic study in 209 patients. Gastroenterology 1985;88:1777-1790.
32. Poupon R, Chazouilleres O, Balkau B, Poupon RE, and the UDCA-PBC Group. Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis. J Hepatol 1999;30:408-412.
33. Corpechot C, Carrat F, Poupon R, Poupon RE. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002;122:652-658.
34. Poupon RE, Lindor KD, Pares A, Chazouilleres O, Poupon R, Heathcote EJ. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003;39:12-16.
35. Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005;128:297-303.
36. Clouston AD, Powell EE, Walsh MJ, Richardson MM, Demetris AJ, Jonsson JR. Fibrosis correlates with a ductular reaction in hepatitis C: Roles of impaired replication, progenitor cells and steatosis. HEPATOLOGY 2005;41:809-818.
37. Lazaridis KN, Strazzabosco M, Larusso NF. The cholangiopathies: disorders of biliary epithelia. Gastroenterology 2004;127:1565-1577.
38. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets. J Cell Mol Med 2006;10:76-99.
39. Van de Water J, Turchany J, Leung PS, Lake J, Munoz S, Surh CD, et al. Molecular mimicry in primary biliary cirrhosis: evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2. J Clin Invest 1993;91:2653-2664.
40. Guldner HH, Szostecki C, Grotzinger T, Will H. Interferon enhance expression of SP100, an autoantigen in primary biliary cirrhosis. J Immunol 1992;149:4067-73.
41. Ferguson TA, Stuart PM, Hemdon JM, Griffith TS. Apoptosis, tolerance, and regulatory T cells: old wine, new wineskins. Immunol Rev 2003; 193: 111-123.
42. Harada K, Ozaki S, Gershwin E, Nakanuma Y. Enhanced apoptosis relates to bile duct loss in primary biliary cirrhosis. HEPATOLOGY 1997;26:1399-1405.
43. Chen M, von Mikecz A. Proteosomal processing of nuclear autoantigens in systemic autoimmunity. Autoimmun Rev 2005;4:117-122.
44. Shimoda S, Nakamura M, Ishibashi H, Hayashida K, Niho Y. HLA DRB4 0101-restricted immunodominant T-cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. J Exp Med 1995;181:1835-1845.
45. Shigematsu H, Shimoda S, Nakamura M, Matsushita S, Nishimura Y, Sakamoto N, et al. Fine specificity of T cells reactive to human PDC-E2 163-176 peptide, the immunodominant autoantigen in primary biliary cirrhosis: implications for molecular mimicry and cross-recognition among mitochondrial autoantigens. HEPATOLOGY 2000;32:901-909.
46. Shimoda S, Nakamura M, Ishibashi H, Kawano A, Kamihira T, Sakamoto N, et al. Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis. Gastroenterology 2003;124:1915-1925.